The UK's Competition and Markets Authority (CMA) has failed to overturn a decision from the Competition Appeal Tribunal (CAT), which set aside certain penalties imposed on Pfizer (NYSE: PFE) and UK-based Flynn Pharma.
The decision relates to charges brought by the CMA, which claimed that the firms breached competition law by charging unfairly high prices for phenytoin sodium capsules, a key anti-epilepsy drug.
Flynn said it was “pleased to receive the judgment,” and criticized the seven-year case from the CMA, saying it was “wrong to use this case to push and test the boundaries of the law.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze